Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
The ‘game changing’ waste-to-energy technology that could catapult PharmAust’s subsidiary Epichem into a $70b market
Health & Biotech
PharmAust’s wholly owned subsidiary Epichem pays off debt in full, ready to accelerate its growth phase
Health & Biotech
PharmAust’s subsidiary Epichem builds ‘world-first’ flow reactor to convert waste into fuel
Health & Biotech
ASX health stocks: Mayne Pharma slapped with lawsuit, Patrys encounters clinical trial delays
News
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech
PharmAust makes progress in the quarter as it lays the foundation for commercialisation
Stockhead TV
Q-Wrapz: Oriel Morrison interviews Roger Aston, executive chairman of PharmAust Ltd (ASX:PAA)
Health & Biotech
PharmAust’s pill significantly protects against COVID-19 virus
Health & Biotech
PharmAust files for patent on lead drug monepantel to fight viral diseases
Health & Biotech
PharmAust signs deal and broadens Monepantel’s scope on antiviral activities
News
Market highlights and 5 ASX small caps to watch on Monday
Health & Biotech
PharmAust flags good news on key stability test for Monepantel treatment
Health & Biotech
PharmAust achieves successful Phase II trials on monepantel for canine cancer, shares jump
News
Market Highlights and 5 ASX Small Caps to watch on Monday
News
ScoPo’s Powerplays: Mental health takes centre stage; Actinogen to progress Alzheimer’s study
Health & Biotech
PharmAust set to commence Phase I trial of Monepantel in patients with motor neurone disease
News
